StemCells, Inc. (NASDAQ:STEM)

CAPS Rating: 2 out of 5

A biopharmaceutical company that operates in one segment, the development of novel cell-based therapeutics designed to treat human diseases and disorders.

Recs

0
Player Avatar chilloutsessions (61.90) Submitted: 3/14/2011 10:04:35 AM : Outperform Start Price: $8.49 STEM Score: -92.84

Long term buy.

Featured Broker Partners


Advertisement